The White House has announced that President Trump has made a deal with Pfizer for state Medicaid to receive most favored nation pricing on Pfizer pharmaceuticals. This is welcome news; however, I do wonder if the rest of the world’s pharmaceutical prices will rise. The White House has released a fact sheet that states:
ADVANCING MOST-FAVORED-NATION PRICING: Today,
President Donald J. Trump announced the first agreement with a major
pharmaceutical company, Pfizer, to bring American drug prices in line with the
lowest paid by other developed nations (known as the most-favored-nation, or
MFN, price).
- The agreement will provide every State Medicaid
program in the country access to MFN drug prices on Pfizer products,
resulting in many millions of dollars in savings and continuing President
Trump’s historic efforts to strengthen the program for the most
vulnerable.
- The agreement ensures foreign nations can no longer
use price controls to freeride on American innovation by guaranteeing MFN
prices on all new innovative medicines Pfizer brings to market.
- The agreement requires Pfizer to repatriate increased
foreign revenue on existing products that Pfizer realizes as a result of
the President’s strong America First U.S. trade policies for the benefit
of American patients.
- The agreement requires Pfizer to offer medicines at a
deep discount off the list price when selling directly to American
patients.
DELIVERING REDUCED COSTS: Today’s actions will result in tangible
cost savings to American patients and the healthcare system as a whole. Taken
together, more than 100 million patients are impacted by the diseases Pfizer’s
medicines treat, and many of those will benefit from the President’s successful
negotiation of lower prices for Americans. Examples include:
- Eucrisa, a topical ointment for atopic dermatitis,
will be made available at an 80% discount to patients purchasing directly.
- Xeljanz, a widely used oral medication for rheumatoid
arthritis, psoriatic arthritis, and ulcerative colitis, will be available
at a 40% discount to patients purchasing directly.
- Zavzpret, a commonly utilized treatment for
migraines, will be sold directly to patients at a 50% discount.
ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION: President
Trump is taking decisive action to rebalance a system that allows
pharmaceutical manufacturers to offer low prices to other wealthy nations while
charging Americans significantly higher prices.
- According to recent data, the prices Americans pay
for brand-name drugs are more than three times the price other
Organization for Economic Cooperation and Development nations pay, even
after accounting for discounts manufacturers provide in the U.S.
- The United States has less than five percent of the
world’s population, yet roughly 75% of global pharmaceutical profits come
from American taxpayers.
- Drug manufacturers benefit from generous research
subsidies and enormous healthcare spending by the U.S. Government. Instead
of passing that benefit through to American consumers, drug manufacturers
then discount their products abroad to gain access to foreign markets and
subsidize those discounts through high prices charged in America.
Americans are subsidizing drug-manufacturer profits and foreign health
systems, both in development and once the drugs are sold.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President
Trump is delivering on promises for American patients that the political
establishment did not believe were possible.
- On May 12, 2025, President Trump signed an Executive
Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to
American Patients” directing the Administration to take numerous actions
to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to
leading pharmaceutical manufacturers outlining the steps they must take to
bring down the prices of prescription drugs in the United States to match
the lowest price offered in other developed nations
- President Trump has been relentless in his effort to
address the unfair and outrageous prices Americans pay for prescription
drugs:
o President
Trump: “In case after case, our citizens pay massively higher prices than other
nations pay for the same exact pill, from the same factory, effectively
subsidizing socialism aboard [abroad] with skyrocketing prices at home. So we
would spend tremendous amounts of money in order to provide inexpensive drugs
to another country. And when I say the price is different, you can see some
examples where the price is beyond anything — four times, five times
different.”